Jolles S, Deacock S, Turnbull W, Silvestrini R, Bunn C, White P, Ward M
Department of Clinical Immunology, Royal Free Hospital, London, UK.
J Clin Pathol. 1999 Mar;52(3):177-80. doi: 10.1136/jcp.52.3.177.
(1) To assess a range of intravenous immunoglobulin products for atypical classical antineutrophil cytoplasmic antibody (C-ANCA) staining and to determine if this is present in patients treated with high dose intravenous immunoglobulin (2 g/kg/month) and replacement doses (200 mg/kg fortnightly); (2) using the United Kingdom national external quality assessment scheme (NEQAS), to determine if laboratories could differentiate this pattern from classical ANCA.
ANCA testing was performed on 30 batches of intravenous immunoglobulin from several manufacturers. Six patients treated with high dose intravenous immunoglobulin and 11 receiving replacement doses of immunoglobulin for hypogammaglobulinaemia were tested for ANCA by indirect immunofluorescence on cytospin preparations of ethanol fixed neutrophils and by enzyme linked immunosorbent assay (ELISA). One of the positive immunoglobulin batches was tested blindly by 125 laboratories involved in NEQAS by indirect immunofluorescence and by ELISA in some laboratories.
16 of 31 batches of intravenous immunoglobulin from six different manufacturers were atypical C-ANCA positive. Three of six patients receiving high dose intravenous immunoglobulin and none of 11 patients on replacement doses were atypical C-ANCA positive. The results of the NEQAS assessment by indirect immunofluorescence were 68% C-ANCA positive, 17% negative, 9% atypical C-ANCA, and 6% P-ANCA.
Some but not all intravenous immunoglobulin products yield a positive atypical cANCA by indirect immunofluorescence. An identical pattern may be observed in patients receiving high dose intravenous immunoglobulin but not in those on replacement doses. Of laboratories participating in NEQAS, 68% reported this pattern as cANCA. This reinforces the importance of reporting only "classical ANCA," defined by international ANCA workshops, to maintain the specificity of ANCA immunofluorescence and its close disease associations.
(1)评估一系列静脉注射免疫球蛋白产品对非典型经典抗中性粒细胞胞浆抗体(C-ANCA)的染色情况,并确定接受高剂量静脉注射免疫球蛋白(2克/千克/月)和替代剂量(每两周200毫克/千克)治疗的患者中是否存在这种情况;(2)利用英国国家外部质量评估计划(NEQAS),确定实验室能否将这种模式与经典ANCA区分开来。
对来自几家制造商的30批次静脉注射免疫球蛋白进行ANCA检测。对6名接受高剂量静脉注射免疫球蛋白治疗的患者和11名因低丙种球蛋白血症接受免疫球蛋白替代剂量治疗的患者,通过对乙醇固定中性粒细胞的细胞涂片制备物进行间接免疫荧光法以及酶联免疫吸附测定(ELISA)来检测ANCA。其中一批阳性免疫球蛋白由参与NEQAS的125个实验室通过间接免疫荧光法进行盲测,部分实验室还通过ELISA进行检测。
来自六个不同制造商的31批次静脉注射免疫球蛋白中,有16批次非典型C-ANCA呈阳性。接受高剂量静脉注射免疫球蛋白的6名患者中有3名非典型C-ANCA呈阳性,而接受替代剂量治疗的11名患者中无一例呈阳性。通过间接免疫荧光法进行的NEQAS评估结果为:C-ANCA阳性68%,阴性17%,非典型C-ANCA 9%,P-ANCA 6%。
部分但并非所有静脉注射免疫球蛋白产品通过间接免疫荧光法可产生非典型cANCA阳性结果。接受高剂量静脉注射免疫球蛋白的患者中可观察到相同模式,但接受替代剂量治疗的患者中未观察到。在参与NEQAS的实验室中,68%将这种模式报告为cANCA。这强化了仅报告国际ANCA研讨会定义的“经典ANCA”的重要性,以维持ANCA免疫荧光的特异性及其与疾病的紧密关联。